

DBT-THSTI team gets patent granted in Japan

New Delhi, March 04: Tuberculosis is one of the leading causes of deaths in humans. The causative agent of tuberculosis (TB), *Mycobacterium tuberculosis* and its drug resistant strains exhibit unique mechanisms to survive in the host. In 2017 an estimated 10 million people developed TB of which 1.3 million died. Approximately 300 000 more HIV-positive deaths were reported due to TB.



A group of researchers at DBT-Translational Health Science and Technology Institute (DBT-THSTI) and Sphaera Pharma Pvt. Ltd. have synthesized novel compounds as anti-tubercular agents and filed patent applications on 29th November 2016. The patent entitled “novel compounds as anti-tubercular agents” has been now granted in Japan with Japanese patent application no. 2017-515286. The collaborators for this patent are Drug Discovery Research Centre, THSTI & Sphaera Pharma Pvt. Ltd. The inventors are Sundeep dugar, Dinesh Mahajan, Santosh Kumar Rai, Kanury Rao and Varshneya Singh.

Contact Person & Contact Details:
Mr. M. V. Santo (santo@thsti.res.in)

Link: <https://www.thsti.res.in/>